Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF

Christopher H. Van Dyck; John P. Seibyl; James B. Stubbs; Sami Zoghbi; Gary Wisnieuiski; Ronald M. Baldwin; Yolanda Zea-Ponce; Dennis S. Charney; Paul B. Hoffer; Robert B. Innis

doi:10.1016/0969-8051(95)02003-9

Human biodistribution and dosimetry of the SPECT D₂ dopamine receptor radioligand [¹²³I]IBF

Christopher H. Van Dyck, John P. Seibyl, James B. Stubbs, Sami Zoghbi, Gary Wisnieuiski, Ronald M. Baldwin, Yolanda Zea-Ponce, Dennis S. Charney, Paul B. Hoffer, Robert B. Innis

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

The research discussed in this article aimed to characterize better the biodistribution, excretion and radiation dosimetry of the single photon emission computed tomography (SPECT) D₂ Dopamine receptor radioligand [¹²³I]IBF. Following administration of 111 ± 12 MBq [¹²³I]IBF, seven healthy human subjects were scanned serially with a whole body imager over a 48-h period. Transmission images were obtained with a scanning line source for attenuation correction of the emission images. Urine was collected for 48 h to measure the fraction of activity voided by the renal system. Radiation absorbed dose estimates were performed using biokinetic modeling and the Medical Internal Radiation Dose (MIRD) schema. Highest absorbed doses were to the kidney (0.13 ± 0.02 mGy/MBq) and urinary bladder wall (0.11 ± 0.01 mGy/ MBq). The effective dose equivalent was 0.041 ± 0.005 mSv/MBq. Peak brain uptake represented 8% of the injected activity. Rapid urinary excretion minimized the absorbed dose to most tissues. The mean cumulative urinary excretion fraction was 69%. Thus [¹²³I]IBF is a promising SPECT agent for imaging the D₂ dopamine receptor in humans with high brain uptake and favorable dosimetry.

Original language	English
Pages (from-to)	9-16
Number of pages	8
Journal	Nuclear Medicine and Biology
Volume	23
Issue number	1
DOIs	https://doi.org/10.1016/0969-8051(95)02003-9
State	Published - Jan 1996
Externally published	Yes

Keywords

D dopamine receptor
Dosimetry
SPECT
[I]iodobenzofuran

Access to Document

10.1016/0969-8051(95)02003-9

Cite this

@article{ede994e688e1433eace21eaf43f0e52c,

title = "Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF",

abstract = "The research discussed in this article aimed to characterize better the biodistribution, excretion and radiation dosimetry of the single photon emission computed tomography (SPECT) D2 Dopamine receptor radioligand [123I]IBF. Following administration of 111 ± 12 MBq [123I]IBF, seven healthy human subjects were scanned serially with a whole body imager over a 48-h period. Transmission images were obtained with a scanning line source for attenuation correction of the emission images. Urine was collected for 48 h to measure the fraction of activity voided by the renal system. Radiation absorbed dose estimates were performed using biokinetic modeling and the Medical Internal Radiation Dose (MIRD) schema. Highest absorbed doses were to the kidney (0.13 ± 0.02 mGy/MBq) and urinary bladder wall (0.11 ± 0.01 mGy/ MBq). The effective dose equivalent was 0.041 ± 0.005 mSv/MBq. Peak brain uptake represented 8% of the injected activity. Rapid urinary excretion minimized the absorbed dose to most tissues. The mean cumulative urinary excretion fraction was 69%. Thus [123I]IBF is a promising SPECT agent for imaging the D2 dopamine receptor in humans with high brain uptake and favorable dosimetry.",

keywords = "D dopamine receptor, Dosimetry, SPECT, [I]iodobenzofuran",

author = "{Van Dyck}, {Christopher H.} and Seibyl, {John P.} and Stubbs, {James B.} and Sami Zoghbi and Gary Wisnieuiski and Baldwin, {Ronald M.} and Yolanda Zea-Ponce and Charney, {Dennis S.} and Hoffer, {Paul B.} and Innis, {Robert B.}",

year = "1996",

month = jan,

doi = "10.1016/0969-8051(95)02003-9",

language = "English",

volume = "23",

pages = "9--16",

journal = "Nuclear Medicine and Biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "1",

}

TY - JOUR

T1 - Human biodistribution and dosimetry of the SPECT D2 dopamine receptor radioligand [123I]IBF

AU - Van Dyck, Christopher H.

AU - Seibyl, John P.

AU - Stubbs, James B.

AU - Zoghbi, Sami

AU - Wisnieuiski, Gary

AU - Baldwin, Ronald M.

AU - Zea-Ponce, Yolanda

AU - Charney, Dennis S.

AU - Hoffer, Paul B.

AU - Innis, Robert B.

PY - 1996/1

Y1 - 1996/1

N2 - The research discussed in this article aimed to characterize better the biodistribution, excretion and radiation dosimetry of the single photon emission computed tomography (SPECT) D2 Dopamine receptor radioligand [123I]IBF. Following administration of 111 ± 12 MBq [123I]IBF, seven healthy human subjects were scanned serially with a whole body imager over a 48-h period. Transmission images were obtained with a scanning line source for attenuation correction of the emission images. Urine was collected for 48 h to measure the fraction of activity voided by the renal system. Radiation absorbed dose estimates were performed using biokinetic modeling and the Medical Internal Radiation Dose (MIRD) schema. Highest absorbed doses were to the kidney (0.13 ± 0.02 mGy/MBq) and urinary bladder wall (0.11 ± 0.01 mGy/ MBq). The effective dose equivalent was 0.041 ± 0.005 mSv/MBq. Peak brain uptake represented 8% of the injected activity. Rapid urinary excretion minimized the absorbed dose to most tissues. The mean cumulative urinary excretion fraction was 69%. Thus [123I]IBF is a promising SPECT agent for imaging the D2 dopamine receptor in humans with high brain uptake and favorable dosimetry.

AB - The research discussed in this article aimed to characterize better the biodistribution, excretion and radiation dosimetry of the single photon emission computed tomography (SPECT) D2 Dopamine receptor radioligand [123I]IBF. Following administration of 111 ± 12 MBq [123I]IBF, seven healthy human subjects were scanned serially with a whole body imager over a 48-h period. Transmission images were obtained with a scanning line source for attenuation correction of the emission images. Urine was collected for 48 h to measure the fraction of activity voided by the renal system. Radiation absorbed dose estimates were performed using biokinetic modeling and the Medical Internal Radiation Dose (MIRD) schema. Highest absorbed doses were to the kidney (0.13 ± 0.02 mGy/MBq) and urinary bladder wall (0.11 ± 0.01 mGy/ MBq). The effective dose equivalent was 0.041 ± 0.005 mSv/MBq. Peak brain uptake represented 8% of the injected activity. Rapid urinary excretion minimized the absorbed dose to most tissues. The mean cumulative urinary excretion fraction was 69%. Thus [123I]IBF is a promising SPECT agent for imaging the D2 dopamine receptor in humans with high brain uptake and favorable dosimetry.

KW - D dopamine receptor

KW - Dosimetry

KW - SPECT

KW - [I]iodobenzofuran

UR - http://www.scopus.com/inward/record.url?scp=0030019857&partnerID=8YFLogxK

U2 - 10.1016/0969-8051(95)02003-9

DO - 10.1016/0969-8051(95)02003-9

M3 - Article

C2 - 9004921

AN - SCOPUS:0030019857

SN - 0969-8051

VL - 23

SP - 9

EP - 16

JO - Nuclear Medicine and Biology

JF - Nuclear Medicine and Biology

IS - 1